Seattle genomics startup Variant Bio signs deal with Novo Nordisk worth up to $50M. by Lisa Stiffler on January 7, 2025 at 10:07 am January 7, 2025 at 10:10 am. Share 7 Tweet Share Reddit Email.

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

COLLABORATION LEVERAGES VARIANT BIO'S CUTTING-EDGE GENOMIC DISCOVERY PLATFORM AND EVOTEC'S INTEGRATED END-TO-END R&D PLATFORM AND DISEASE AREA EXPERTISE TO ADDRESS UNMET MEDICAL NEED IN FIBROTIC ...

About Variant Bio and Ethical, People-Driven Therapeutics. Seattle-based Variant Bio utilizes genetics, molecular biology, and anthropology to identify relevant communities with whom it partners.

Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes. By Brendan Borrell When Stephane Castel first ...

Variant Bio has entered a multi-year research partnership with Novo Nordisk, focusing on the identification of new targets to treat metabolic conditions. Leveraging Variant’s ‘VB-Inference ...

Evotec and Variant Bio enter strategic partnership to discover and develop fibrosis treatments 18.04.2024 / 13:27 CET/CEST The issuer is solely responsible for the content of this announcement ...